Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its ...

Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the saf ...

1 Additional data from both the ARCADIA program in atopic dermatitis, as well as from the OLYMPIA open-label extension study in prurigo nodularis will be presented at RAD 2025, reinforcing ...

9 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis.

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib and abrocitinib.

If you have a darker skin tone, you might see small, hardened, very itchy bumps, known as prurigo nodularis, on areas of your skin affected by atopic dermatitis. You may also be likely to get ...

1 Additional data from both the ARCADIA program in atopic dermatitis, as well as from the OLYMPIA open-label extension study in prurigo nodularis will be presented at RAD 2025, reinforcing Nemluvio’s ...

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis ... disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.